Efficacy and safety of recombinant human growth hormone in the treatment of idiopathic short stature
孙志刚 1马延博 1田春利 1马艳丽
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 聊城市第二人民医院儿童保健科，临清 252600
折叠
摘要
目的 探讨重组人生长激素(rhGH)治疗特发性矮小症(ISS)的有效性及安全性。 方法 回顾性抽取2020年10月至2022年11月聊城市第二人民医院收治的ISS患儿78例。按照治疗方案将其分为研究组(39例，给予rhGH联合常规治疗)和对照组(39例，给予单纯常规治疗)。比较两组治疗前后身高测量值，分析两组治疗前后25-羟基维生素D[25-(OH)D]、骨钙素(OC)等骨代谢相关指标，比较两组不良反应发生情况。 结果 治疗前，两组身高测量值、25-(OH)D水平、OC水平比较差异未见统计学意义(P>0.05)；治疗后，两组身高测量值、25-(OH)D水平、OC水平高于治疗前(P<0.05)，且研究组高于对照组(P<0.05)。用药期间，两组各项药物所致不良反应发生率比较，差异未见统计学意义(P>0.05)。 结论 rhGH治疗ISS疗效显著，有利于改善患儿骨代谢情况，且有一定的安全性。 Objective To investigate the efficacy and safety of recombinant human growth hormone (rhGH) in the treatment of idiopathic short stature (ISS). Methods A total of 78 children with ISS admitted to Liaocheng Second People’s Hospital from October 2020 to November 2022 were retrospectively selected. According to the treatment plan, they were divided into the study group (39 cases, treated with rhGH combined with conventional treatment) and the control group (39 cases, treated with conventional treatment alone). The preoperative and postoperative body heights of the two groups were compared. The bone metabolism-related indexes including 25-hydroxyvitamin D, referred to as 25-(OH)D, and osteocalcin (OC) were compared between the two groups before and after treatment. The incidences of adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in the body height, 25-(OH)D level and OC level between the two groups (P>0.05). After treatment, the body height, 25-(OH)D level, and OC level in the two groups were higher than those before treatment (P<0.05), and the above indicators in the study group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of drug-induced adverse reactions between the two groups (P>0.05). Conclusions rhGH has significant efficacy in the treatment of ISS, which is conducive to improving bone metabolism in children with a certain safety.
Abstract
Objective To investigate the efficacy and safety of recombinant human growth hormone (rhGH) in the treatment of idiopathic short stature (ISS). Methods A total of 78 children with ISS admitted to Liaocheng Second People’s Hospital from October 2020 to November 2022 were retrospectively selected. According to the treatment plan, they were divided into the study group (39 cases, treated with rhGH combined with conventional treatment) and the control group (39 cases, treated with conventional treatment alone). The preoperative and postoperative body heights of the two groups were compared. The bone metabolism-related indexes including 25-hydroxyvitamin D, referred to as 25-(OH)D, and osteocalcin (OC) were compared between the two groups before and after treatment. The incidences of adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in the body height, 25-(OH)D level and OC level between the two groups (P>0.05). After treatment, the body height, 25-(OH)D level, and OC level in the two groups were higher than those before treatment (P<0.05), and the above indicators in the study group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of drug-induced adverse reactions between the two groups (P>0.05). Conclusions rhGH has significant efficacy in the treatment of ISS, which is conducive to improving bone metabolism in children with a certain safety.
关键词
人生长激素/特发性矮小症/骨代谢
Key words
Human growth hormone/Idiopathic short stature/Bone metabolism
万方数据